Evaluating the Effects of Snack Products on Energy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01544816
Recruitment Status : Completed
First Posted : March 6, 2012
Last Update Posted : May 8, 2013
Cognitive Research Corporation
Mercer University
Information provided by (Responsible Party):
Mondelēz International, Inc.

February 24, 2012
March 6, 2012
May 8, 2013
February 2012
August 2012   (Final data collection date for primary outcome measure)
Energy questionnaire OR Rating of perceived energy OR Subjective feeling of energy (visual analog scale) [ Time Frame: 90 minutes post snack ]
Same as current
Complete list of historical versions of study NCT01544816 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Evaluating the Effects of Snack Products on Energy
Not Provided
To determine the effect of snack products varying in composition, on energy in healthy adult subjects.
Not Provided
Not Applicable
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
  • Other: Snack Product
    control food product
  • Other: Snack Product
    Experimental food product containing ingredient 1
  • Other: Snack Product
    Experimental food product containing ingredient 2
  • Placebo Comparator: Control Food Product
    Control food product
    Intervention: Other: Snack Product
  • Experimental: Experimental Food Product 1
    Experimental food product 1
    Intervention: Other: Snack Product
  • Experimental: Experimental Food Product 2
    Experimental food product 2
    Intervention: Other: Snack Product
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
August 2012
August 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. The subject must provide informed consent.
  2. The subject is male or female, and between the ages of 20 and 45, inclusive.
  3. The subject is a routine, moderate daily user of caffeine (approximately 1-4 cups of coffee or equivalent).
  4. The subject is fluent in English.
  5. The subject has a minimum of a high school diploma.
  6. Females of Child-bearing Potential (FOCP) must have a negative urine or serum beta HCG pregnancy test at screening. FOCP must abstain from sexual activity that could result in a pregnancy, or use acceptable contraceptives throughout the period of study treatment exposure. Acceptable contraceptives include IUDs, hormonal contraceptives (oral, implanted or injectable) and double barrier methods (such as condom or diaphragm with spermicidal gel). If hormonal contraceptives are used, the period of use must be sufficiently long to achieve pharmacological effectiveness prior to study treatment exposure (refer to individual product information for details on onset of effectiveness). FOCP who are not currently sexually active, must agree to use acceptable contraception, as defined above, if they decide to become sexually active during the period of study treatment exposure .
  7. The subject is in good physical and mental health based on a general medical history.
  8. The subject has adequate visual and auditory acuity and cognitive ability to complete the assessments and is capable of understanding and following instructions for the performance tests within the normal, age-adjusted range (within one SD) at screening.
  9. Must be able and willing to obtain a minimum of 7 hours of sleep the night prior to each study visit.
  10. The subject is willing and able to comply with all requirements defined within this protocol.
  11. The subject reports having a snack at least two afternoons per week.
  12. The subject reports experiencing an "afternoon slump".

Exclusion Criteria

  1. The subject has a current Axis I or Axis II comorbid psychiatric diagnosis or other symptomatic manifestations that, in the opinion of the examining physician (Investigator), will contraindicate treatment with caffeine.
  2. Attention Deficit Disorder or Attention Deficit Hyperactivity Disorder
  3. BMI ≤ 19 or ≥ 30 kg/m2.
  4. The subject has documented allergies, adverse reactions, or intolerance to caffeine.
  5. The subject has any significant medical illness or condition for which caffeine is contraindicated.
  6. The subject has a history of drug dependence or substance use disorder based upon DSM-IV-TR criteria (excluding nicotine).
  7. The subject has a positive urine drug or alcohol drug test result (to include nicotine).
  8. The subject has participated in an investigational study or received an investigational drug within the past 28 days.
  9. The subject has used nicotine products within 30 days of screening or during the duration of the study.
  10. The subject is taking medications, that have CNS effects or affect performance, (such as sedating antihistamines and decongestant sympathomimetics, either oral or topical), and may interfere with efficacy or safety assessments.
  11. The subject has a concurrent chronic or acute illness (such as allergic rhinitis or severe cold), disability, or other condition that might confound the results of rating tests administered in the study or that might increase risk to the subject. Similarly, the subject will be excluded if he or she has any additional conditions that, in the Investigator's opinion, would preclude the subject from completing the study or would not be in the best interest of the subject. This would include any significant illness or unstable medical condition that could lead to difficulty complying with the protocol.
  12. The female subject is pregnant or lactating or planning on becoming pregnant during the study
  13. Hypertension or other chronic medical conditions
  14. Individuals who do not maintain a routine nighttime sleep schedule (e.g. no shift work).
  15. Individuals judged by the Investigator to be unsuitable for enrollment in this study for any reason.
  16. The subject has been diagnosed with phenylketonuria.
  17. Inability to perform performance tests within the Normal range (i.e., performance no lower than 1SD below the mean) at screening.
  18. The subject has a pre-existing medical condition.
  19. Subject has been diagnosed with a sleeping disorder.
  20. Subject has a fasting glucose of >110 mg/dl.
  21. Subject has an allergy to wheat, soy, nuts or other food.
  22. Subject has Kosher or Halal dietary restrictions.
  23. Subject reports never eating biscuits, cookies or crackers.
  24. Epworth Sleepiness Scale ≥ at screening (i.e., evidence of excessive daytime sleepiness).
  25. Dislike of chocolate flavorings
Sexes Eligible for Study: All
20 Years to 45 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Mondelēz International, Inc.
Mondelēz International, Inc.
  • Cognitive Research Corporation
  • Mercer University
Principal Investigator: Chad VanDenBerg, Pharm.D. Mercer University
Mondelēz International, Inc.
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP